(Z)-Ajoene

(Z)-Ajoene

SCHEMBL3305767

C=CCSS/C=C\C[S+]([O-])CC=C

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.46
TRPA1 O75762 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
HPGD P15428 2/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ajoene SCHEMBL3341704 1.00 PTGS2 (0.46) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL465526 1.00 PTGS2 (0.46) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL1843901 1.00 PTGS2 (0.46) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL3341700 1.00 PTGS2 (0.46) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL17873665 0.90 PTGS2 (0.39) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL28098809 0.90 PTGS2 (0.39) PTGS2TRPA1ALDH1A1CYP3A4HPGD
Ajoene SCHEMBL17785554 0.90 PTGS2 (0.42) PTGS2TRPA1ALDH1A1CYP3A4HPGD
SCHEMBL10728699 0.86 PTGS2 (0.34) PTGS2
SCHEMBL10728691 0.86 PTGS2 (0.34) PTGS2
SCHEMBL10728708 0.86 PTGS2 (0.34) PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709166-A1 NOVEL INSECTICIDAL MIXTURES FOR CONTROLLING AND PROTECTING CROPS ADAMA MAKHTESHIM LTD. (IL) 2026-03-18 EP claimed
EP-4637733-A1 TREATMENT OF MYELOPEROXIDASE-POSITIVE ANCA-ASSOCIATED VASCULITIS WITH H2S RELEASING COMPOUNDS Debreceni Egyetem (HU) 2025-10-29 EP claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
WO-2024231927-A1 NOVEL INSECTICIDAL MIXTURES FOR CONTROLLING AND PROTECTING CROPS ADAMA MAKHTESHIM LTD. (IL) 2024-11-14 WO claimed
WO-2024134235-A1 TREATMENT OF MYELOPEROXIDASE-POSITIVE ANCA-ASSOCIATED VASCULITIS WITH H2S RELEASING COMPOUNDS DEBRECENI EGYETEM (HU) 2024-06-27 WO claimed
CN-103328441-A Process for the manufacture of ajoene derivatives UNIV DENMARK TECH DTU 2013-09-25 CN claimed
EP-2110128-A1 USE OF PARTICULAR ANTIBACTERIAL COMPOUNDS, WHICH ARE DERIVED FROM ALLIACEAE, AS NATURAL ADDITIVES IN ANIMAL FEED DMC Research Center, S.L. (ES) 2009-10-21 EP claimed
US-7321002-B2 Chiral integrin modulators and methods of use thereof BILLINGS PHARMACEUTICALS, INC. (US) 2008-01-22 US claimed
US-20060205824-A1 Chiral integrin modulators and methods of use thereof BILLINGS PHARMACEUTICALS, INC. 2006-09-14 US claimed
US-7045663-B2 Chiral integrin modulators and methods of use thereof BILLINGS PHARMACEUTICALS, INC. (US) 2006-05-16 US claimed
EP-1309548-A4 CHIRAL INTEGRIN MODULATORS AND METHODS OF USE THEREOF BILLINGS PHARMACEUTICALS INC (US) 2005-10-05 EP claimed
WO-2002004413-A9 CHIRAL INTEGRIN MODULATORS AND METHODS OF USE THEREOF DAVIDSON JOHN B (US) 2004-05-06 WO claimed
US-20040053892-A1 Chiral integrin modulators and methods of use thereof BILLINGS PHARMACEUTICALS, INC. 2004-03-18 US claimed
EP-1309548-A1 CHIRAL INTEGRIN MODULATORS AND METHODS OF USE THEREOF Billings Pharmaceuticals, Inc. (US) 2003-05-14 EP claimed
WO-2002004413-A1 CHIRAL INTEGRIN MODULATORS AND METHODS OF USE THEREOF DAVIDSON JOHN B (US) 2002-01-17 WO claimed
JP-8012570-A None JP disclosed
EP-4709166-A1 NOVEL INSECTICIDAL MIXTURES FOR CONTROLLING AND PROTECTING CROPS ADAMA MAKHTESHIM LTD. (IL) 2026-03-18 EP disclosed
US-4643994-A ANTICOAGULANTS, ANTIBIOTICS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1987-02-17 US disclosed
EP-0185324-A2 Novel organic trithio oxides and method for the preparation thereof THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1986-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205824-A1 Chiral integrin modulators and methods of use thereof ITGB1, ITGB5, ITGB3 PTGS2 2962/4885TRPA1 1023/4885ALDH1A1 289/4885
US-20040053892-A1 Chiral integrin modulators and methods of use thereof ITGB1, ITGA1, ITGAM PTGS2 2449/4885TRPA1 1231/4885ALDH1A1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.